Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Athletes Beware Banned by WADA/USADA 10
doi: 10.1158/1078-0432.CCR-22-3350 23 RuiRZhouLHeS
This retrospective cohort study included 3,389 adult patients with obesity who initiated treatment with injectable semaglutide or liraglutide between July 1, 2015, and June 30, 2022
With oral GLP-1 formulations entering the market and a broader pipeline of next-generation agents on the horizon, benefit leaders now need a second layer of analysis: how today's trajectory informs spend projections as the product landscape expands
US$ 22.43
US$ 21.64
US$ 27.09
US$ 25.41
